Reported 8 months ago
After acquiring a foothold in the US market through mergers, the biotech leader Purzer has also initiated alliances with Taiwanese pharmaceutical companies to compete internationally. Purzer announced on June 24, 2024, that they will be manufacturing the recently approved ophthalmic drug APP13007 from TSC, and together they aim to capture a $1.3 billion ophthalmic post-operative medication market annually in the US. This collaboration combines TSC's drug technology expertise with Purzer's manufacturing capabilities, showcasing Taiwan's strengths in new drug development and exportation.
Source: YAHOO